Infección (bacteriana)

AKG and its calcium salt (Ca-AKG) have demonstrated anti-osteoporotic effects in both human trials and animal models. In postmenopausal women, Ca-AKG 6 g/day for 6 months reduced bone resorption marker CTX and improved lumbar BMD. In aged mice, AKG attenuated age-related bone loss by reducing senescence of bone marrow mesenchymal stem cells via histone demethylation.

Anemarrhena is used in TCM formulas specifically for postmenopausal osteoporosis, and preclinical studies demonstrate that its active compounds increase bone mineral density in OVX mouse models, modulate RANKL/OPG signaling, and inhibit ferroptosis-driven bone resorption.

Annatto-derived tocotrienols have demonstrated anti-osteoporotic effects in one human RCT (89 postmenopausal osteopenic women, 12 weeks) and multiple animal models using postmenopausal and testosterone-deficient rat models. The human trial showed reduced bone resorption biomarkers and improved bone turnover. Long-term bone mineral density studies in humans remain to be conducted.

Apigenin is a flavone found in parsley, celery, and chamomile with documented anti-osteoporotic effects in preclinical studies. It inhibits osteoclastogenesis, promotes osteoblast differentiation, and has ERβ agonist activity relevant for postmenopausal bone protection. Multiple animal models confirm apigenin prevents bone loss.

Astaxanthin is a powerful xanthophyll carotenoid from Haematococcus pluvialis with anti-inflammatory and antioxidant properties relevant to bone health. Preclinical studies show astaxanthin inhibits osteoclast differentiation and reduces inflammatory cytokine-driven bone resorption. It has been identified in nutraceutical osteoporosis reviews as an emerging bone-protective antioxidant.

Bamboo is among the richest plant sources of silica, which is positively associated with bone mineral density in epidemiological studies and stimulates bone formation markers in clinical trials. Silica promotes osteoblast activity, collagen synthesis, and bone matrix mineralization. Traditional medicine uses bamboo (vanshlochan) specifically for osteoporosis.

Barrenwort (Epimedium, Yin Yang Huo) is a Traditional Chinese Medicine herb whose active compound icariin promotes osteoblast differentiation and inhibits osteoclastogenesis. Clinical trials of Epimedium-derived phytoestrogen flavonoids in postmenopausal women have shown reduced bone loss. It has been used in TCM for centuries for bone weakness and kidney deficiency.

Black cohosh has been clinically evaluated for effects on bone metabolism in postmenopausal women. Studies show improvements in bone turnover markers, with one trial demonstrating stimulation of osteoblast activity. However, evidence on direct improvement in bone mineral density is conflicting and fracture prevention is unestablished.

Boron is a trace mineral that supports bone health by reducing urinary excretion of calcium and magnesium and by raising serum vitamin D levels. A 2020 research review found boron supplementation may help prevent bone loss, with an intake of 3 mg/day suggested as sufficient. A 2024 pilot study found improved bone density with increased boron intake in postmenopausal women.

Sulforaphane from broccoli inhibits osteoclast activity (bone resorption) and reduces oxidative stress in bone cells, with preclinical evidence suggesting protection against osteoporosis. Broccoli is also a dietary source of vitamin K and calcium, essential for bone mineralization. A 2021 study linked sulforaphane to inhibition of osteoclasts that break down bone mass.

Brussels sprouts are among the richest food sources of vitamin K1 (~270% DV per cooked cup), which activates osteocalcin to mineralize bone. They also supply folate that reduces homocysteine — high homocysteine is independently associated with a 4% increased fracture risk per µmol/L increment in meta-analysis.

Cabbage is a significant source of vitamin K1, providing approximately 56–136% of the daily value per cup depending on preparation. Vitamin K is essential for activating osteocalcin, the bone matrix protein that regulates calcium incorporation into bone. Inadequate vitamin K is linked to lower bone density and increased fracture risk, particularly in older adults.

Calcium is the primary mineral component of bone and the most evidence-backed nutrient for osteoporosis prevention. NIH Consensus guidelines recommend 1,000–1,500 mg/day for postmenopausal women and the elderly to slow bone loss. Prospective studies confirm calcium slows postmenopausal bone loss and improves bone density across life stages.

CB2 receptor activation by BCP is mechanistically linked to bone health, including increased bone mineralization and modulation of bone marrow stem cell differentiation. A USPTO patent method specifically proposes BCP for osteoporosis prevention via these mechanisms.

Green tea catechins—particularly EGCG—reduce bone loss by modulating RANK/RANKL/OPG signaling, stimulating osteoblast differentiation, and inhibiting osteoclastogenesis. Clinical and epidemiological data suggest habitual green tea consumption is associated with higher bone mineral density and reduced osteoporosis risk.

Cauliflower's vitamin K1 and vitamin C content support bone collagen matrix integrity and osteocalcin-mediated mineralization. Human meta-analyses of vitamin K supplementation demonstrate significant BMD improvements and fracture risk reduction, establishing a scientific basis for cruciferous vegetable intake in osteoporosis prevention.

Chia seeds are a concentrated source of calcium, phosphorus, magnesium, and manganese — all critical for bone matrix integrity and remodeling. Animal data show increased bone mineral content and density with long-term chia intake. Human-specific chia RCTs for bone outcomes are not yet available.

Salvia miltiorrhiza has been studied in 38+ clinical trials for osteoporosis management, showing efficacy rates of 77–96.67%. Its compounds inhibit osteoclastogenesis and promote osteoblast activity through multiple signaling pathways. Both ethanol (tanshinones) and water (salvianolic acids) extracts contribute to bone-protective effects.

Chondroitin sulfate is a glycosaminoglycan structural component of bone matrix and cartilage. Some studies indicate chondroitin supplementation may support bone health and reduce bone resorption markers. Epidemiological data (Million Women Study) found chondroitin users had lower rates of bone loss, and combined glucosamine-chondroitin supplementation is widely used for musculoskeletal health including bone preservation.

Cissus quadrangularis (Hadjod) is a traditional Ayurvedic 'bone setter' herb used for millennia in fracture healing and osteoporosis. Modern studies show it inhibits RANKL-induced osteoclastogenesis, promotes osteoblast differentiation, and improves bone micro-architecture in ovariectomized animal models. Preclinical evidence for osteoporosis is strong, with some clinical data supporting its bone-protective effects.

CLA, particularly the t10,c12 isomer, has shown potential to enhance bone mineral density and reduce bone resorption in preclinical models. Preliminary human data from RA patients show positive effects on bone turnover markers. Direct clinical evidence for osteoporosis prevention in the general population is limited.

Cod liver oil's vitamin D supports intestinal calcium absorption and bone mineralization, directly opposing the mechanisms of osteoporosis. Clinical data show vitamin D supplementation increases bone mineral density at the lumbar spine and femoral neck, reducing fracture risk. CLO has been used as an osteoporosis prevention strategy since the 20th century.

The same 12-week RCT that demonstrated increased bone mass with forskolin in men (Godard 2005) also provides the foundation for osteoporosis prevention claims. Increased bone mass via cAMP-driven osteoblast activation is the proposed mechanism. Evidence is from one small study only.

Collagen constitutes approximately 90% of bone's protein matrix, providing the flexible scaffold for mineral deposition. Specific collagen peptides (SCP) supplementation at 5 g/day improved BMD of the spine and femoral neck significantly in a placebo-controlled RCT of 131 postmenopausal women. A PMC review confirmed collagen peptides show a positive effect on bone strength and mineral density, with evidence of increased bone formation markers.

Collard greens provide approximately 27% DV calcium and over 883% DV vitamin K per cooked cup. Vitamin K activates osteocalcin and other bone-building proteins necessary for calcium incorporation into bone mineral. Low vitamin K intake has been linked observationally to increased fracture risk, and research supports adequate calcium intake as protective against osteoporosis and fractures.

Bovine colostrum is the first milk produced after birth, rich in IGF-1, IGF-2, and other growth factors that stimulate osteoblast activity and bone formation. Studies suggest colostrum supplementation can improve bone markers and may offer bone-protective effects, particularly in postmenopausal women and athletes. Its IGF-1 content specifically supports bone anabolic processes.

Copper is a trace mineral required as a cofactor for lysyl oxidase, the enzyme that crosslinks collagen and elastin in bone matrix. Copper deficiency impairs collagen crosslinking, reducing bone strength, and has been associated with increased osteoporosis risk. It is listed among essential bone health minerals in comprehensive nutritional reviews.

A 2021 meta-analysis of 15 studies (100,496 individuals) found high BCX intake significantly reduced osteoporosis risk by 21% (OR=0.79). BCX stimulates osteoblastic bone formation and inhibits osteoclastic resorption via NF-κB suppression and TGF-β/SMAD activation. Epidemiological studies in postmenopausal women consistently support this association.

Curcumin, the active polyphenol from turmeric, has demonstrated significant bone-protective effects in preclinical models via OPG/RANKL, Wnt/β-catenin, and NF-κB signaling pathways. A 2025 meta-analysis of animal studies found curcumin significantly increased femoral and tibial BMD and improved trabecular microstructure. Clinical trials in postmenopausal osteoporosis show improved bone turnover markers when combined with standard therapy.

Daidzein is a soy isoflavone shown to stimulate osteoblast differentiation and inhibit osteoclast activity via multiple signaling pathways. Clinical trials of daidzein-containing isoflavone mixtures have shown reduced lumbar spine bone loss in postmenopausal women. It is the most widely studied soy phytoestrogen for bone health alongside genistein.

Daidzin and daidzein have demonstrated anti-osteoporotic effects in ovariectomized animal models through promotion of osteogenesis and inhibition of osteoclastogenesis. A comparative study of soy isoflavones including daidzin showed bone loss reduction in ovariectomized rats. Clinical evidence from mixed isoflavone RCTs suggests modest benefits.

DHA is a long-chain n-3 PUFA that reduces pro-inflammatory bone-resorbing cytokines and supports osteoblast function. Preclinical evidence and epidemiological data link higher DHA intake to better bone density and reduced osteoporosis risk. Combined with EPA in fish oil studies, DHA-containing supplementation has shown improvements in bone formation markers in clinical trials.

Age-related DHEA/DHEAS reduction is associated with osteopenia and osteoporosis. Clinical and epidemiological studies support DHEA replacement as potentially beneficial for bone health, primarily in women. A Mendelian randomization study causally linked endogenous DHEAS to lumbar spine BMD and forearm fracture risk in women. Typical dose studied is 50 mg/day orally.

In an ovariectomized mouse model mimicking postmenopausal bone loss, DIM significantly increased bone mass by suppressing osteoclastic bone resorption. A separate study in zebrafish and MC3T3-E1 preosteoblasts confirmed DIM promotes bone formation via BAP1/IP3R/SOCE signaling. No human clinical trials on bone density outcomes have been published.

Dioscorea alata extract (Dispo85E) promoted osteoblastogenesis, increased bone mineral density, and ameliorated trabecular bone deterioration in ovariectomised mice in a PMC-published study. Animal studies also link dioscorin to enhanced bone mineral density via estrogenic mechanisms. No human RCTs exist.

Cuscuta chinensis has been used in China and other Asian countries for osteoporosis treatment for centuries, and is now one of the most pharmacologically studied herbs for this indication. Multiple studies show its active constituents (kaempferol, hyperoside, quercetin, isorhamnetin) prevent bone loss via RANKL/OPG, Wnt/β-catenin, and BMP/Smad pathways. In vivo rat studies show increased bone mineral density and reduced osteoclast activity.

Animal studies demonstrate that A. sinensis extract significantly increases bone mineral density in ovariectomized rats via estrogen-independent mechanisms. Ligustilide promotes bone formation via the GPR30/EGFR pathway. Ferulic acid promotes bone remodeling toward an osteoblastic phase and increases serum estrogen and ALP activity. These findings are entirely preclinical; no human clinical trials have been conducted.

Drynaria (Drynaria fortunei, 'Gu Sui Bu') is a classical Traditional Chinese Medicine herb used for over 1,000 years for bone fractures, weakness, and osteoporosis. Modern studies confirm it promotes osteoblast differentiation, stimulates bone formation, and inhibits bone resorption in in vitro and animal models.

EGCG inhibits osteoclast formation via the RANKL/OPG axis, promotes osteoblast proliferation and bone mineralization, and protects against glucocorticoid-induced bone loss. Population data show habitual tea drinkers have measurably higher BMD and lower fracture rates, and animal studies confirm direct EGCG-mediated protection.

Eggs supply vitamin D and high-quality protein, two established nutrients for bone density maintenance. Observational data associate whole egg consumption with higher bone mineral density in children and older adults, and a retrospective study in Spain linked eggs to protection against vitamin D deficiency-induced osteoporosis.

EPA is an n-3 PUFA that inhibits bone resorption by suppressing prostaglandin E2-mediated osteoclast activation and inflammatory cytokines. Combined EPA+GLA supplementation for 18 months increased lumbar spine density by 3.1% and femoral BMD by 4.7% in a clinical trial of elderly osteoporotic women. Preclinical data confirm EPA enhances calcium absorption and bone formation.

E. ulmoides has been validated in multiple RCTs (animal models) and preliminary human studies for osteoporosis prevention, demonstrating consistent improvements in BMD and bone microarchitecture. Its multi-pathway mechanisms target both bone formation and resorption. This is one of the best-characterized areas of eucommia research.

Eucommia ulmoides (Du Zhong) is a Traditional Chinese Medicine herb used for kidney and bone health, with scientific studies confirming it prevents disuse-induced osteoporosis in animal models. Active compounds including chlorogenic acid, aucubin, and geniposide promote osteoblast activity and inhibit osteoclastogenesis. A peer-reviewed study confirmed Du-zhong prevents disuse-induced osteoporosis in hind limb suspension rats.

Clinical evidence for EPO in osteoporosis prevention comes from a small number of trials in postmenopausal and elderly women, primarily using EPO combined with fish oil and calcium. One 18-month RCT found significant BMD maintenance and modest density gain in osteopenic/osteoporotic elderly women. Evidence in healthy populations is negative.

Ferulic acid prevents bone loss by inhibiting RANKL/NF-κB-driven osteoclastogenesis and activating SIRT1-mediated bone protective pathways. Rodent data show large BMD gains (25–142% depending on dose) in glucocorticoid-induced osteoporosis models. Evidence is exclusively preclinical; human osteoporosis trials are not yet available.

Fisetin is a bioactive flavonol found in strawberries, apples, and other fruits that inhibits osteoclast differentiation and promotes osteoblast activity in preclinical models. It also has senolytic properties relevant to age-related osteoporosis, as senescent cells in bone marrow drive bone loss. Preclinical evidence from multiple studies consistently supports fisetin's bone-protective potential.

Flaxseed is the richest dietary source of the plant lignan secoisolariciresinol diglucoside (SDG), which is metabolized to bone-protective phytoestrogens (enterolactone, enterodiol). Small clinical studies show flaxseed supplementation (40 g/day) reduces bone resorption markers in postmenopausal women. Flaxseed also provides alpha-linolenic acid (ALA), the plant n-3 PUFA with emerging bone health evidence.

Folate (folic acid) reduces plasma homocysteine, elevated levels of which impair collagen crosslinking in bone matrix and are independently associated with increased fracture risk. Combined B-vitamin supplementation (including folic acid, B12, B6) has been shown in Japanese clinical trials to reduce fracture risk. Folate inadequacy is common in the elderly and represents a modifiable bone health risk.

Formononetin is a methoxylated isoflavone found primarily in red clover and alfalfa that is metabolized to daidzein and equol in the body. Red clover-derived formononetin-containing extracts have demonstrated reduced lumbar bone loss in postmenopausal women in a placebo-controlled RCT. It has estrogenic activity at ERβ receptors in bone tissue.

A 2019 Nutrients study demonstrated that a water extract of Forsythia suspensa significantly reduced ovariectomy-induced trabecular bone loss and inhibited RANKL-driven osteoclast formation in mice. A 2024 study showed forsythoside A mitigates diabetes-related osteoporosis via NRF2/GPX4. Evidence is preclinical; no human trials have been conducted.

FOS enhances colonic calcium and magnesium absorption via SCFA-mediated pH reduction, a mechanism linked to improved bone mineral content in animal models. Human evidence supports improved calcium absorption, with a 24-month RCT in 300 postmenopausal women showing effects on bone turnover markers when combined with calcium supplementation.

Genistein is the predominant soy isoflavone with the strongest evidence for bone protection among the phytoestrogens. A randomized double-blind placebo-controlled study found genistein alone significantly reduced bone loss in early postmenopausal women compared to placebo. A meta-analysis identified genistein at 54 mg/day as having beneficial effects on BMD in postmenopausal women.

GLA combined with EPA supplementation has been shown in a pilot RCT to preserve and modestly increase bone mineral density in elderly women, supporting a role in osteoporosis prevention. Animal data consistently show GLA enhances calcium absorption and deposition. Evidence is preliminary but mechanistically grounded.

Glucosamine is an amino sugar that is a structural component of glycosaminoglycans in cartilage and bone matrix. Some research suggests glucosamine may modestly support bone health and reduce osteoporotic fracture risk. Epidemiological data indicate glucosamine users have lower rates of bone loss and may have reduced hip fracture risk.

Anti-osteoporosis effects are among the most consistently cited health attributes of glycitin in peer-reviewed literature. Soy isoflavone class evidence from systematic reviews and RCTs supports a bone-protective role, particularly in postmenopausal women experiencing estrogen-deficiency bone loss. Glycitein's SERM-like activity on bone tissue is the proposed primary mechanism.

In an ovariectomized rat model of postmenopausal osteoporosis, oral S. scardica extract (300 mg/kg, 20 weeks) produced significantly increased bone mineral density and improved biomechanical bone strength compared to untreated ovariectomized controls. A separate 6-month rat study confirmed protective effects on bone density in Sideritis euboea. No human clinical trials have been conducted.

Hesperetin is the aglycone metabolite of hesperidin with documented anti-osteoporotic activity in an ovariectomized mouse model. It improved bone volume ratio and bone thickness and decreased trabecular separation per a study cited in the Frontiers in Nutrition (2024) osteoporosis nutraceuticals review. It also has demonstrated bone resorption-inhibiting effects.

Hesperidin is a citrus flavanone glycoside found in orange peel with multiple preclinical anti-osteoporotic effects. It promotes osteogenesis of mesenchymal stem cells, improves bone volume ratio and thickness in ovariectomized mouse osteoporosis models, and inhibits bone resorption. The Frontiers in Nutrition (2024) nutraceuticals in osteoporosis review specifically identified hesperidin's protective role in bone health.

HMR lignan (7-hydroxymatairesinol) from Norway spruce knots is a concentrated plant lignan efficiently converted by gut bacteria to enterolactone, a mammalian lignan with ERβ agonist bone-protective activity. Studies show HMR supplementation significantly raises serum enterolactone concentrations, and epidemiological data link higher enterolactone with better BMD in postmenopausal women.

HMR Lignan is a proprietary form of 7-hydroxymatairesinol from Norway spruce knots that is efficiently converted by gut bacteria to enterolactone, a phytoestrogen associated with bone protection in postmenopausal women. Clinical studies confirm HMR Lignan supplementation significantly raises serum enterolactone levels. Higher enterolactone concentrations are epidemiologically linked to better BMD.

Horny goat weed (Epimedium) contains icariin, a flavonoid that promotes osteoblast differentiation and inhibits osteoclastogenesis. A 2-year clinical trial in postmenopausal women found Epimedium-derived total flavone supplementation reduced bone loss significantly compared to calcium alone. It has been used in TCM for centuries for bone weakness and kidney deficiency.

Horsetail (Equisetum arvense) is a silicon-rich plant traditionally used for bone and connective tissue health in European herbalism. Its high orthosilicic acid content is proposed to stimulate bone mineralization and collagen synthesis. The Frontiers in Nutrition (2024) osteoporosis nutraceuticals review identified horsetail's silica, flavonoids, and triterpenoids as beneficial for bone health.

Icariin is the principal active flavonoid glycoside from Epimedium (Horny Goat Weed/Yin Yang Huo), a traditional Chinese herb used for bone and kidney health. Multiple preclinical studies demonstrate icariin promotes osteoblast differentiation, inhibits osteoclastogenesis, and prevents ovariectomy-induced bone loss. Some clinical trials in postmenopausal women show icariin-containing Epimedium extracts increase BMD.

By consistently enhancing calcium and magnesium absorption across clinical trials spanning adolescents, adult women, and postmenopausal women, inulin-type fructans may reduce osteoporosis risk. A one-year adolescent trial demonstrated improved bone mineral content. Osteoporosis-specific prevention data in older at-risk populations remains limited.

Ipriflavone (7-isopropoxyisoflavone) is a synthetic isoflavone derivative studied specifically for osteoporosis prevention and treatment. A multicenter 2-year RCT showed significant increases in bone mineral density with ipriflavone treatment versus placebo in senile osteoporosis patients. A JAMA trial (n=475, 3 years) found no effect on bone loss, illustrating conflicting evidence.

Soy isoflavones (genistein, daidzein, formononetin, biochanin A) are phytoestrogens that bind estrogen receptors in bone tissue, inhibiting osteoclast activity and stimulating osteoblast differentiation. A meta-analysis of 63 RCTs found genistein (54 mg/day) and ipriflavone (600 mg/day) had beneficial effects on BMD in postmenopausal women. Results across trials are mixed but overall support modest bone-protective effects.

Kaempferol is a flavonol found in many plants (broccoli, tea, kale) with documented anti-osteoporotic effects in preclinical studies. It promotes osteoblast differentiation, inhibits osteoclastogenesis, and has ERβ agonist activity. The Frontiers in Nutrition (2024) nutraceuticals in osteoporosis review identified kaempferol among bone-protective phytochemicals.

Kale provides vitamin K1 (essential for osteocalcin carboxylation), calcium, and magnesium—all relevant to bone health and osteoporosis prevention. Cross-sectional studies link low vitamin K1 levels to osteoporosis in postmenopausal women. Combined vitamin K and calcium supplementation in RCTs modestly improves lumbar BMD. Kale has been traditionally used for bone health in several cultures.

Kudzu isoflavones (puerarin, daidzein) act as phytoestrogens via ERβ, reducing bone resorption and showing efficacy in postmenopausal bone loss models. A clinical RCT in menopausal women demonstrated significant reductions in the bone resorption marker CTX-I. Preclinical data in ovariectomized mice confirm anti-osteoporotic effects.

L. rhamnosus GG demonstrates bone-protective effects in ovariectomized animal models by correcting Th17/Treg imbalance and improving bone microarchitecture, biomechanics, and turnover markers. A 2010 double-blind RCT documented improved bone mineral density and bone turnover markers in postmenopausal women. The gut-bone axis is a mechanistically supported pathway.

Lactoferrin stimulates osteoblast proliferation and inhibits osteoclast activity through multiple pathways, with robust animal model data and emerging but limited human evidence. Ovariectomized rat studies demonstrate BMD preservation and improved trabecular architecture with oral lactoferrin. Human RCT data specifically for osteoporosis prevention remain limited.

Lignans are plant polyphenols (found in flaxseed, sesame, whole grains) that are metabolized by gut bacteria to enterolactone and enterodiol—mammalian lignans with weak estrogenic activity in bone. Higher enterolactone concentrations have been positively associated with BMD in cross-sectional studies. Lignans represent the primary phytoestrogen class in Western diets with emerging bone-protective evidence.

Luteolin is a flavone found in celery, broccoli, and herbs that inhibits osteoclast differentiation and promotes osteoblast activity in preclinical studies. The Frontiers in Nutrition (2024) osteoporosis nutraceuticals review identified luteolin as a bone-protective phytochemical. It inhibits RANKL-induced osteoclastogenesis via NF-κB suppression.

Closely related to bone density, lycopene supplementation is specifically evaluated for osteoporosis prevention in postmenopausal women. Evidence from clinical studies shows reductions in urinary bone resorption markers and modulation of osteoblast/osteoclast activity. The mechanism involves lycopene's antioxidant reduction of oxidative-stress-driven bone loss.

Animal models consistently show maca prevents estrogen-deficient bone loss dose-dependently, with identified bioactive constituents acting on estrogen receptors in osteoblasts. Traditional Andean use includes bone health support for aging populations. Human clinical data are not yet available.

Magnesium is the second most abundant mineral in bone and is essential for vitamin D activation and calcium metabolism. Low magnesium is associated with increased osteoporosis risk, and supplementation (as citrate, carbonate, or oxide) may protect bone density and reduce fracture risk per a 2021 research review. Magnesium deficiency promotes osteoclast activity and disrupts calcium homeostasis.

Manganese is a trace mineral that serves as a cofactor for enzymes required in glycosaminoglycan and proteoglycan synthesis in bone matrix. Inadequate manganese intake impairs bone formation, and it is listed among essential bone health minerals by major nutritional authorities. Low manganese is associated with increased bone resorption and reduced bone density.

MCHC is derived from bovine bone and contains calcium, phosphorus, collagen, and bone growth factors in a form that closely resembles natural bone mineral. Several RCTs found MCHC supplementation resulted in slower rates of BMD loss in postmenopausal women compared to calcium carbonate or placebo. Its bone-similar composition is proposed to offer advantages over standard calcium salts.

Melatonin is a pineal hormone that directly promotes osteoblastogenesis and suppresses osteoclastogenesis via MT2 receptors in mesenchymal stem cells and bone cells. Multiple reviews confirm melatonin supplementation improves bone mass in rodent osteoporosis models, and several clinical trials indicate bone mass-conserving effects in aging and postmenopausal osteoporosis. It also improves gut ecology to support bone metabolism.

Finger millet's exceptionally high calcium content and documented effects on bone mineral density, calcium retention, and bone resorption markers support its use in osteoporosis prevention. Clinical data show reduced bone resorption markers and improved BMD in supplementation trials. Millet is recommended in Ayurvedic and modern dietary guidance for bone loss prevention.

Morinda officinalis root extracts inhibit bone loss through dual action: stimulating osteoblast differentiation (via BMP-SMAD signalling) and suppressing osteoclast activity (via NF-κB inhibition). These effects have been reproducibly demonstrated in ovariectomized rodent models of postmenopausal osteoporosis.

Naringin prevents osteoporosis in multiple animal models by promoting osteoblast differentiation, increasing BMD, and inhibiting osteoclastogenesis via Wnt/β-catenin, JAK2/STAT3, and BMP-2/Runx2 pathways. A meta-analysis of 10 OVX rat studies showed a significant BMD increase (WMD 0.06; p<0.01). Naringin has a long history of use in TCM preparations for fractures and bone weakness.

OA demonstrates consistent bone-protective effects in ovariectomized and aged animal models by increasing bone mineral density, improving bone microarchitecture, modulating calcium homeostasis, and activating vitamin D synthesis enzymes. It is considered a candidate for postmenopausal osteoporosis prevention.

Olive oil and its polyphenols have demonstrated bone-protective effects in animal models of osteoporosis and in human observational studies. Hydroxytyrosol inhibits multinucleated osteoclast formation and suppresses trabecular bone loss in ovariectomized animal models. Human data link olive oil intake to improved bone mineral density and fracture reduction.

Omega-3 fatty acids (EPA, DHA, ALA) have preclinical and epidemiological evidence consistently suggesting benefit for bone health, including inhibition of bone resorption and enhanced calcium absorption. A systematic review of 10 RCTs found mixed results, with one 18-month trial showing significant BMD improvement in osteoporotic elderly women. Animal studies show omega-3s inhibit bone breakdown and enhance bone strength.

Onion flavonoid extract significantly increased bone mineral density in ovariectomized rat models of postmenopausal osteoporosis, with effects comparable to alendronate sodium. Onion inhibits RANKL-induced osteoclastogenesis and promotes osteoblast proliferation and mineralization. Population data show more frequent onion consumers have higher bone density.

Palm tocotrienols demonstrate anti-osteoporotic activity in rodent models by reducing oxidative stress-driven bone loss, improving BMD, and favorably altering bone remodeling markers. A human RCT in postmenopausal osteopenic women showed reduced bone resorption biomarkers. The evidence base is still primarily preclinical with emerging clinical support.

Berberine from P. amurense has shown in small-scale clinical trials to improve bone mineral density in postmenopausal women and reduce bone turnover markers. Preclinical studies confirm berberine's mechanisms for inhibiting osteoclastogenesis and promoting osteoblast activity. Phellodendron species are reviewed as 'promising' for osteoporosis treatment in a 2024 peer-reviewed Chinese Journal of Integrative Medicine paper.

Phosphorus is the second most abundant mineral in bone, comprising about 85% of the body's phosphorus stores in bone as hydroxyapatite. Adequate phosphorus intake alongside calcium is recognized as essential for bone formation and is among the current recommendations for osteoporosis prevention nutrients. Imbalances in calcium-to-phosphorus ratio can adversely affect bone density.

Phytoestrogens are plant-derived compounds (isoflavones, lignans, coumestans) that bind estrogen receptors in bone tissue and exert bone-protective effects by reducing osteoclast activity and promoting osteoblast function. Multiple RCTs and meta-analyses support their role in attenuating postmenopausal bone loss, with the strongest evidence for isoflavones (genistein, daidzein) and lignans.

Multiple observational studies and RCT evidence link higher potassium intake—particularly from alkaline-forming salts such as potassium citrate and bicarbonate—to reduced bone resorption markers and greater BMD, supporting a role in osteoporosis prevention. The mechanism centers on neutralizing diet-derived acid loads that would otherwise mobilize calcium from bone.

Animal and in vitro studies consistently show FLL prevents bone loss and increases bone mineral density via osteoclast inhibition and vitamin D metabolism modulation. Key constituents include oleanolic acid, ursolic acid, salidroside, and nuzhenide. The PMC 2018 review concludes FLL is a promising anti-osteoporotic agent pending human trials.

Progesterone and progestins support bone formation by stimulating osteoblasts via progesterone receptors, adding to estrogen's antiresorptive bone protection. A meta-analysis of 5 RCTs (n=1,058 menopausal women) found combined estrogen-progestogen therapy produces +0.68%/year greater spinal BMD gain than estrogen alone. Women with anovulatory cycles lose approximately 1% vertebral BMD per year, implicating progesterone deficiency in osteoporosis development.

Prunes are documented as a functional food intervention for osteoporosis prevention in postmenopausal women, the highest-risk demographic. Clinical and preclinical evidence shows prevention and reversal of bone loss via anti-resorptive and anti-inflammatory mechanisms. Sixteen rodent studies and at least two human RCTs support the osteoprotective case.

Quercetin is a flavonoid with preclinical evidence demonstrating inhibition of osteoclast differentiation and promotion of osteoblast activity via multiple signaling pathways. The Frontiers in Nutrition (2024) osteoporosis nutraceuticals review identified quercetin among bone-protective phytochemicals. Animal studies consistently show quercetin prevents ovariectomy-induced bone loss.

Red clover is rich in isoflavones (biochanin A, formononetin, genistein, daidzein) that act as phytoestrogens with bone-protective effects. A 12-month double-blind RCT in 205 postmenopausal women showed red clover-derived isoflavones significantly reduced lumbar spine BMD loss compared to placebo. It is one of the most-studied botanical sources of phytoestrogens for postmenopausal bone health.

Rehmannia Radix Preparata has been studied extensively in preclinical osteoporosis models with consistent BMD-protective effects. Animal studies in OVX and glucocorticoid-induced osteoporosis models show significant inhibition of BMD loss via osteoblastogenesis promotion and osteoclastogenesis suppression. Clinical pharmacological reviews confirm its use for postmenopausal and senile osteoporosis in China.

Rehmanniae Radix demonstrates anti-osteoporotic effects across multiple animal models of both estrogen-deficient and glucocorticoid-induced osteoporosis, with documented clinical use in over 107 osteoporosis clinical studies (in TCM co-prescriptions). It stimulates osteoblasts, inhibits osteoclasts, and enhances BMD independently of estrogen.

Resveratrol is a polyphenol with evidence from a 12-month placebo-controlled RCT showing increased BMD at the lumbar spine and femoral neck and reduced bone resorption markers in postmenopausal women. A 24-month RCT in osteopenic postmenopausal women also provided clinical evidence of bone protection, with the greatest benefit in women with poor bone health biomarker status.

Preclinical evidence from rat and zebrafish models shows safflower (seed extract and HSYA) enhances osteoblast markers, promotes bone formation, and inhibits bone resorption. Korean folk medicine uses safflower seeds specifically to prevent osteoporosis. Multiple authoritative PMC reviews classify safflower as 'osteoporosis-preventative.'

The BMC 2016 study (PMC4994400) directly concluded that EEST is a potential agent for treating osteoclast-related bone diseases such as osteoporosis, based on RANKL-induced osteoclastogenesis inhibition in vitro and LPS-induced bone erosion protection in vivo. Evidence is preclinical only.

Secoisolariciresinol diglucoside (SDG) is the primary plant lignan in flaxseed, converted by gut bacteria to enterodiol and enterolactone—mammalian phytoestrogens with ERβ-mediated bone-protective effects. Flaxseed supplementation providing SDG has been shown to reduce bone resorption markers in postmenopausal women. Higher enterolactone (SDG metabolite) is epidemiologically associated with better BMD.

The literature, including multiple reviews, supports sesame's role in postmenopausal osteoporosis prevention via calcium, mineral content, and lignan-mediated phytoestrogenic activity. A comprehensive review confirmed sesame seeds have a positive impact on postmenopausal women with bone-related problems. Mechanistic data on sesamin and enterolactone modulating estrogen receptors to reduce bone resorption are established, though large-scale human RCTs on fracture endpoints are lacking.

Shiitake's vitamin D2 content (from UV exposure) supports calcium absorption critical for bone density maintenance, the primary preventive mechanism for osteoporosis. UV-irradiated shiitake raised serum 25(OH)D2 in human studies and showed bone-protective effects in ovariectomized animal models. Copper and zinc in shiitake further support bone structural integrity.

Silicon (as orthosilicic acid) is an essential mineral for bone formation, required for collagen synthesis and bone mineralization independent of vitamin D. A 2013 PMC review identified silicon deficiency as important and widespread, with growing evidence for its role in preventing postmenopausal osteoporosis. Epidemiological studies show higher dietary silicon intake is associated with better BMD.

Silymarin shows osteogenic preclinical evidence relevant to osteoporosis prevention, including enhanced osteoblast differentiation and bone mineral density in animal fracture models. Pro-estrogenic receptor activity provides a mechanistic link to postmenopausal bone loss. Human clinical trials for osteoporosis prevention specifically have not yet been conducted.

Animal and in vitro research specifically targeting osteoporosis demonstrates that Polygonatum polysaccharides suppress osteoclastogenesis and promote osteoblast formation, with effects confirmed in ovariectomized rodent models. Evidence is preclinical only; human trials are absent.

Soy isoflavones have a documented evidence base for modest attenuation of bone loss and reduction in bone resorption markers in postmenopausal women, supporting a role in osteoporosis prevention. Evidence is strongest for lumbar spine BMD. Fracture prevention data are lacking.

Soy isoflavones are phytoestrogens with documented bone-protective effects in menopausal women. A meta-analysis showed soy isoflavone intake inhibits bone resorption and stimulates bone formation in menopausal women. The MDPI 2021 meta-analysis of 63 RCTs found beneficial effects on BMD from soy isoflavones, though results are mixed across individual trials.

Soy isoflavones have been evaluated in multiple RCTs and meta-analyses for osteoporosis prevention, primarily in postmenopausal women. Evidence supports modest improvements in lumbar spine BMD and reduction in bone resorption markers. Results at hip sites are less consistent. Clinical data suggest approximately 80 mg/day isoflavones are needed to derive skeletal benefits.

Spinach is a leading dietary source of vitamin K1, which activates osteocalcin for calcium binding in bone matrix. Meta-analyses of RCTs confirm vitamin K supplementation significantly reduces vertebral fracture risk (OR ~0.42). Spinach also provides calcium and magnesium relevant to bone mineralisation.

Resolvins directly inhibit osteoclast activity, potentially mediating bone preservation. SPMs promote bone regeneration and remodeling in preclinical models. Human periodontal bone loss studies show SPMs protect alveolar bone. A scoping review of SPMs in craniofacial bone regeneration identified 19 preclinical studies.

Strontium can be incorporated into bone cells in place of calcium, increasing bone density and reducing the risk of osteopenia and osteoporosis. Strontium ranelate is an approved pharmaceutical for osteoporosis in several countries, though elemental strontium supplements are less well-studied. Preclinical and mechanistic research supports strontium's dual action of promoting bone formation and inhibiting resorption.

Multiple peer-reviewed preclinical studies have demonstrated that Dipsacus asper extracts, asperosaponin VI, and Dipsacus asper polysaccharides inhibit osteoclastogenesis, promote osteoblast differentiation, and increase bone mineral density in ovariectomized rat models. The Chinese and Korean Pharmacopoeias list osteoporosis as a primary indication for Radix Dipsaci. No human clinical trials exist.

T. cordifolia's Beta-ecdysone induces osteogenic differentiation in mesenchymal stem cells and relieves osteoporosis in animal models. An ovariectomized rat study showed significant prevention of bone loss without uterine/mammary proliferative effects. In vitro, ethanolic extract stimulated osteoblast growth, differentiation, and bone matrix mineralization.

Preclinical evidence is strong: tocotrienols inhibit osteoclastogenesis, enhance osteoblast differentiation, and reverse bone loss in multiple animal osteoporosis models. Epidemiological data support a link between vitamin E intake and reduced age-related bone loss. Human clinical trials have not yet been completed but are underway.

Several human epidemiological and pilot clinical studies indicate that lycopene from tomatoes reduces bone loss and fracture risk, particularly in postmenopausal women. Lycopene suppresses RANKL-driven osteoclastogenesis and promotes osteoblast activity via the WNT pathway, providing a plausible mechanism for osteoporosis prevention.

GGOH promotes osteoblast activity, mineralization, and bone-forming gene expression while inhibiting osteoclastogenesis, supporting the bone remodeling balance required to prevent osteoporosis. It is mechanistically relevant as an antidote to bisphosphonate-induced suppression of bone cell function (MRONJ). Evidence is primarily from in vitro human osteoblast and osteoclast studies.

Vitamin A (retinol and beta-carotene) is required for osteoblast and osteoclast regulation, and deficiency impairs bone formation. Epidemiological data (NHANES cross-sectional study) show vitamin A intake is linked with decreased osteoporosis prevalence. However, excessive preformed vitamin A (retinol) can paradoxically increase fracture risk, making optimal intake important.

Vitamin B12 deficiency has been associated with increased bone resorption markers, lower BMD, and elevated homocysteine levels, which independently increase osteoporosis and fracture risk. Epidemiological studies link low B12 status with reduced BMD in older adults. While specific B12 supplementation RCTs for osteoporosis are limited, adequate B12 status is recommended as part of bone health maintenance.

A 2025 NHANES-based cross-sectional study in 4,241 US female adults found that higher dietary riboflavin intake was significantly and negatively associated with femur osteoporosis risk (OR=0.61 for highest vs. lowest quartile) and positively associated with bone mineral density. The proposed mechanism involves riboflavin's antioxidant effects reducing oxidative stress—a known contributor to bone loss.

Vitamin B6 (pyridoxine) lowers plasma homocysteine alongside folate and B12, and homocysteine elevation is an independent risk factor for osteoporotic fracture. Deficiency of B6 impairs collagen crosslinking in bone matrix. Combined B-vitamin supplementation including B6 has been studied for fracture prevention with some positive outcomes in high-risk populations.

Vitamin C (ascorbic acid) is essential for collagen synthesis, which forms the organic matrix of bone. It also inhibits osteoclast activity and stimulates osteoblast maturation. Epidemiological studies show higher dietary vitamin C intake is associated with greater BMD and lower osteoporosis prevalence. A PMC review confirmed its role in osteoporosis development and prevention, though intervention evidence is less conclusive than for calcium/vitamin D.

Vitamin D is essential for intestinal calcium absorption and bone mineralization, and is universally recommended alongside calcium for osteoporosis prevention. Clinical guidelines from NIH, IOF, and WHO identify vitamin D deficiency as a major modifiable osteoporosis risk factor. Combined supplementation with calcium significantly increases BMD in postmenopausal women per multiple RCTs.

Vitamin D3 (cholecalciferol) is the preferred supplemental form of vitamin D for osteoporosis prevention, more potent at raising serum 25(OH)D than D2. It is universally included in osteoporosis management guidelines. RCTs confirm its role, especially when combined with calcium, in increasing BMD and reducing fracture risk in older adults.

Vitamin K is required for carboxylation of osteocalcin, a key bone matrix protein that facilitates calcium binding in bone. A systematic review and meta-analysis of 20 RCTs found vitamin K supplementation reduced overall fracture risk by more than half (OR 0.42 for vertebral fractures). Dietary insufficiency of vitamin K is widely prevalent and considered an important contributor to bone health.

Wasabi leafstalk-derived p-hydroxycinnamic acid (HCA) stimulates osteoblast activity and inhibits osteoclast formation, and in animal models reversed bone loss from ovariectomy and diabetic states. These findings support wasabi's potential role in osteoporosis prevention via dual osteogenic and anti-resorptive mechanisms. Evidence is entirely preclinical.

Whey protein is a complete, rapidly-absorbed milk protein that stimulates IGF-1 production, which is anabolic for bone tissue. Higher protein diets including whey have been associated with better BMD and lower fracture risk in older adults. Whey's high leucine content stimulates muscle protein synthesis, supporting the muscle-bone functional unit important for osteoporosis prevention.

The same human RCT and animal data supporting bone density improvement also apply to osteoporosis. PMA-zeolite clinoptilolite improved bone mineral density and bone formation markers in an osteoporosis patient trial, and completely reversed osteoporotic histomorphometric decline in an ovariectomized rat model. A 4-year ongoing clinical trial further tracks its safety and effects in osteoporosis patients.

Zinc plays a critical role in bone matrix synthesis and osteoblast function. Low zinc status is associated with reduced bone density and increased osteoporosis risk. It is listed among the essential minerals for osteoporosis prevention by major nutritional authorities, and supplementation studies demonstrate improved bone formation markers.

Alfalfa is a legume rich in phytoestrogens (formononetin, coumestrol) and calcium, traditionally used in herbalism for bone and menopausal health. As noted in MDPI's Botanicals in Postmenopausal Osteoporosis review (2021), alfalfa belongs to the legume family alongside red clover and contains isoflavones relevant for bone health. Coumestrol from alfalfa has demonstrated estrogenic bone-protective activity in preclinical models.

Almonds are traditionally associated with bone strengthening due to their rich supply of calcium, magnesium, phosphorus, and vitamin E. While preclinical studies and nutritional composition data support plausible mechanisms for osteoporosis prevention, human RCTs specifically targeting almond consumption and BMD or fracture risk as primary endpoints are not yet published.

Gymnema sylvestre appears in Ayurvedic and ethnobotanical records as a traditional remedy for osteoporosis. This is catalogued by several authoritative pharmacological reviews. No mechanistic preclinical studies or human trials specifically examining GS effects on bone density or osteoporosis exist.

Osteoporosis is listed among the traditional medicinal uses of Shi Jue Ming in TCM. Preliminary in vitro findings show abalone gastrointestinal digests from Haliotis discus hannai promote osteoblast activity, but human evidence is absent.

Nettle is used in Moroccan traditional medicine and other ethnomedicinal systems for bone and joint disorders. Its mineral content (calcium, magnesium, silica) and vitamin K are nutritionally relevant to bone health. Animal data suggest osteoblast-stimulating and osteoclast-inhibiting effects. No human clinical trials on osteoporosis prevention have been conducted.

Wild yam's phytoestrogenic diosgenin has been theorized to support bone density via estrogen receptor interaction, and a Dioscorea protein (DOT) was shown in animal studies to augment bone mineral density and counteract osteoporosis progression. Human clinical trials have not confirmed any bone-protective effect of wild yam supplementation.